Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03987880
Recruitment Status : Active, not recruiting
First Posted : June 17, 2019
Last Update Posted : June 18, 2019
Sponsor:
Collaborator:
Avedro, Inc.
Information provided by (Responsible Party):
Anders Behndig, Umeå University

Brief Summary:
To assess the improvement in refractive error and the corneal endothelial safety with a customized corneal crosslinking treatment regimen for low grade myopia. The study compares two treatment protocols, a 4.0-mm central ring-shaped zone with a 3.5-mm central ring-shaped zone in high oxygen environment without corneal epithelial debridement.

Condition or disease Intervention/treatment Phase
Myopia Corneal Crosslinking Refractive Errors Eye Diseases Procedure: 4.0 mm treatment Procedure: 3.5 mm treatment Not Applicable

Detailed Description:

The study design is a prospective, single-masked intraindividually comparing randomized controlled trial, conducted at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study includes healthy men and women with low grade myopia, aged between 18-35 years and involves 27 participants with a myopia of -0.5 to -2.5 diopters (D) and astigmatism of ≤0.75D. All participants are treated with phototherapeutic intrastromal corneal collagen cross-linking (PiXL) without epithelial debridement (epi-on), after topical riboflavin. Both eyes are treated and randomized to receive ultraviolet (UV) light according to PiXL 4.0 mm treatment zone in one eye and PiXL 3.5 mm treatment zone in the other, which is masked to the participant. For myopia <0.75D, 10 J/cm^2 is used and for higher levels of myopia 15J/cm^2 is used. Throughout the treatment, humidified oxygen is continuously delivered around the eye using an oxygen mask to achieve an oxygen concentration of ≥95 percentage. All participants are informed about the procedures and provide oral and written consent before inclusion in the study.

At baseline, each eye is examined with slit-lamp microscopy, subjective refraction, determination of uncorrected (UCVA), low contrast visual acuity at 2.5 percentage and 10 percentage contrast and best corrected (BSCVA) visual acuities using the LogMAR fast protocol and intraocular pressure (IOP) using Goldmann applanation tonometry. Under standardized, mesopic light conditions each eye is evaluated by keratometry readings, central corneal thickness and after treatment also the depth of demarcation lines, extracted from Schemipflug camera measurements, Pentacam HR® (Oculus, Inc. Lynnwood, WA). Central corneal endothelial photographs are taken with the Topcon SP-2000P specular microscope (Topcon Europe B.V., Capelle a/d Ijssel, the Netherlands), from which the corneal endothelial cell count is manually calculated from a cluster of 25 cells from each photograph. Total ocular wavefront is measured with iTrace (Tracey Technologies, Inc.).

All the above mentioned examinations are reassessed at 1, 3 and 6 and 12 months after treatment. At 1 day and 1 week after treatment, solely UCVA, Auto refractor measurements, slit-lamp examination and a subjective comparison of discomfort and visual performance in each eye are evaluated.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive ultraviolet (UV) light according to protocol A in one eye and protocol B in the other, which is masked to the participant. Both eyes will be treated during the same visit. Participants are randomized utilizing a computer list of unique random numbers between 1 and 27; an even number will be treated with the 4.0-mm zone in the right eye; an uneven number with the 4.0-mm zone in the left eye.
Masking: Single (Participant)
Masking Description: The participants are not aware which eye will receive the 4.0-mm ring-shaped zone treatment and which eye will receive the 3.5-mm ring-shaped zone treatment.
Primary Purpose: Treatment
Official Title: Comparison of a 4-mm Ring Shaped and 3.5-mm Ring Shaped PiXL Protocol for Low Grade Myopia
Actual Study Start Date : January 22, 2018
Estimated Primary Completion Date : March 22, 2020
Estimated Study Completion Date : March 22, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 4.0 mm zone
PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
Procedure: 4.0 mm treatment
PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.

Experimental: 3.5 mm zone
PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
Procedure: 3.5 mm treatment
PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.




Primary Outcome Measures :
  1. Change from baseline in uncorrected visual acuity [ Time Frame: 1, 3, 6, 12 and 24 months after treatment ]
    Change from baseline in distance uncorrected visual acuity

  2. Change from baseline in spherical equivalent [ Time Frame: 1, 3, 6, 12 and 24 months after treatment ]
    Change from baseline in spherical equivalent on subjective distance refraction


Secondary Outcome Measures :
  1. Change from baseline in corneal endothelial cell density [ Time Frame: 12 and 24 months after treatment ]
    Change from baseline in central corneal endothelial cell density

  2. Change from baseline in best corrected visual acuity [ Time Frame: 1, 3, 6, 12 and 24 months after treatment ]
    Change from baseline in best spectacle corrected distance visual acuity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Spherical equivalent on distance subjective refraction between -0.50D and -2.50D.

  • Astigmatism ≤ 0.75D
  • Stable myopia. Maximum change in refraction of 0.50D in the last 2 years.
  • Best corrected visual acuity of at least 0.00 logMAR (ETDRS chart).
  • Thinnest pachymetry reading ≥ 440 μm.
  • No previous ocular surgery.
  • No cognitive insufficiency interfering with the informed consent.

Exclusion Criteria:

  • History of or current condition, disease, surgery or medication with ocular effects that could affect the outcomes of the treatment.
  • Allergy to any substance or device used in the study.
  • Cognitive insufficiency interfering with the informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03987880


Locations
Layout table for location information
Sweden
Department of Clinical Sciences/Ophthalmology, Umeå University
Umeå, Sweden, 901 85
Sponsors and Collaborators
Umeå University
Avedro, Inc.

Layout table for additonal information
Responsible Party: Anders Behndig, Principal Investigator, Umeå University
ClinicalTrials.gov Identifier: NCT03987880     History of Changes
Other Study ID Numbers: PiXLMYOP-II
First Posted: June 17, 2019    Key Record Dates
Last Update Posted: June 18, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Myopia
Refractive Errors
Eye Diseases